Home / Business and Economy / Kura Oncology's KOMZIFTI Dominates AML Market
Kura Oncology's KOMZIFTI Dominates AML Market
13 Aug
Summary
- KOMZIFTI captured majority share in its market niche.
- New patient starts grew 35% and total prescriptions rose 60%.
- Physicians see potential for KOMZIFTI in combination therapies.
Kura Oncology reported robust second-quarter performance for its acute myeloid leukemia treatment, KOMZIFTI. The drug has achieved a leadership position in the menin inhibitor market for relapsed or refractory NPM1-mutated AML, securing a majority share of new patient starts.
During the second quarter, KOMZIFTI experienced substantial growth, with new patient starts increasing by approximately 35% and total prescriptions rising by about 60% from the prior period. This expansion was driven by repeat prescribing and new physician adoption across academic and community treatment centers.
Physician-initiated combination use of KOMZIFTI with other treatments, such as venetoclax and azacitidine, accounted for about 40% of new patient starts. This trend suggests clinicians recognize KOMZIFTI's potential as part of broader AML treatment strategies beyond its approved monotherapy indication.
